Abstract
Triple-negative breast cancers (TNBC) that produce nitric oxide (NO) are more aggressive, and the expression of the inducible form of nitric oxide synthase (NOS2) is a negative prognostic indicator. In these studies, we set out to investigate potential therapeutic strategies to counter the tumor-permissive properties of NO. We found that exposure to NO increased proliferation of TNBC cells and that treatment with the histone deacetylase inhibitor Vorinostat (SAHA) prevented this proliferation. When histone acetylation was measured in response to NO and/or SAHA, NO significantly decreased acetylation on histone 3 lysine 9 (H3K9ac) and SAHA increased H3K9ac. If NO and SAHA were sequentially administered to cells (in either order), an increase in acetylation was observed in all cases. Mechanistic studies suggest that the “deacetylase” activity of NO does not involve S-nitrosothiols or soluble guanylyl cyclase activation. The observed decrease in histone acetylation by NO required the interaction of NO with cellular iron pools and may be an overriding effect of NO-mediated increases in histone methylation at the same lysine residues. Our data revealed a novel pathway interaction of Vorinostat and provides new insight in therapeutic strategy for aggressive TNBCs.
Acknowledgments
This research was supported in part by “bridge funding” from the UICancer Center.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This research was supported in part by “bridge funding” from the UICancer Center.
Conflict of interest statement: The authors declare no conflicts of interest regarding this article.
References
Bubna, A.K. (2015). Vorinostat-an overview. Indian J. Dermatol. 60: 419, https://doi.org/10.4103/0019-5154.160511.Search in Google Scholar
De Paepe, B., Verstraeten, V.M., De Potter, C.R., and Bullock, G.R. (2002). Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem. Cell Biol. 117: 13–19, https://doi.org/10.1007/s00418-001-0356-0.Search in Google Scholar
Dumitrescu, R.G. (2018). Interplay between genetic and epigenetic changes in breast cancer subtypes. Methods Mol. Biol. 1856: 19–34, https://doi.org/10.1007/978-1-4939-8751-1_2.Search in Google Scholar
Garmpis, N., Damaskos, C., Garmpi, A., Kalampokas, E., Kalampokas, T., Spartalis, E., Daskalopoulou, A., Valsami, S., Kontos, M., Nonni, A., et al.. (2017). Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises. Cancer Genomics Proteomics 14: 299–313, https://doi.org/10.10.21873/cgp.20041.Search in Google Scholar
Glynn, S.A., Boersma, B.J., Dorsey, T.H., Yi, M., Yfantis, H.G., Ridnour, L.A., Martin, D.N., Switzer, C.H., Hudson, R.S., Wink, D.A., et al.. (2010). Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J. Clin. Invest. 120: 3843–3854, https://doi.org/10.1172/jci42059.Search in Google Scholar
Griffith, D.M., Szocs, B., Keogh, T., Suponitsky, K.Y., Farkas, E., Buglyo, P., and Marmion, C.J. (2011). Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes. J. Inorg. Biochem. 105: 763–769, https://doi.org/10.1016/j.jinorgbio.2011.03.003.Search in Google Scholar
Hebbel, R.P., Vercellotti, G.M., Pace, B.S., Solovey, A.N., Kollander, R., Abanonu, C.F., Nguyen, J., Vineyard, J.V., Belcher, J.D., Abdulla, F., et al.. (2010). The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 115: 2483–2490, https://doi.org/10.1182/blood-2009-02-204990.Search in Google Scholar
Heinecke, J.L., Ridnour, L.A., Cheng, R.Y., Switzer, C.H., Lizardo, M.M., Khanna, C., Glynn, S.A., Hussain, S.P., Young, H.A., Ambs, S., et al.. (2014). Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 111: 6323–6328, https://doi.org/10.1073/pnas.1401799111.Search in Google Scholar
Hickok, J.R., Sahni, S., Mikhed, Y., Bonini, M.G., and Thomas, D.D. (2011a). Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron. J. Biol. Chem. 286: 41413–41424, https://doi.org/10.1074/jbc.m111.287052.Search in Google Scholar
Hickok, J.R., Sahni, S., Shen, H., Arvind, A., Antoniou, C., Fung, L.W., and Thomas, D.D. (2011b). Dinitrosyliron complexes are the most abundant nitric oxide-derived cellular adduct: biological parameters of assembly and disappearance. Free Radic. Biol. Med. 51: 1558–1566, https://doi.org/10.1016/j.freeradbiomed.2011.06.030.Search in Google Scholar
Hickok, J.R. and Thomas, D.D. (2010). Nitric oxide and cancer therapy: the emperor has NO clothes. Curr. Pharmaceut. Des. 16: 381–391, https://doi.org/10.2174/138161210790232149.Search in Google Scholar
Hickok, J.R., Vasudevan, D., Antholine, W.E., and Thomas, D.D. (2013). Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases. J. Biol. Chem. 288: 16004–16015, https://doi.org/10.1074/jbc.m112.432294.Search in Google Scholar
Hickok, J.R., Vasudevan, D., Thatcher, G.R., and Thomas, D.D. (2012). Is S-nitrosocysteine a true surrogate for nitric oxide? Antioxidants Redox Signal. 17: 962–968, https://doi.org/10.1089/ars.2012.4543.Search in Google Scholar
Kroncke, K.D. (2001). Zinc finger proteins as molecular targets for nitric oxide-mediated gene regulation. Antioxidants Redox Signal. 3: 565–575, https://doi.org/10.1089/15230860152542934.Search in Google Scholar
Loibl, S., Buck, A., Strank, C., von Minckwitz, G., Roller, M., Sinn, H.P., Schini-Kerth, V., Solbach, C., Strebhardt, K., and Kaufmann, M. (2005). The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur. J. Canc. 41: 265–271. https://doi.org/10.1016/j.ejca.2004.07.010.Search in Google Scholar
MacArthur, P.H., Shiva, S., and Gladwin, M.T. (2007). Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851: 93–105, https://doi.org/10.1016/j.jchromb.2006.12.012.Search in Google Scholar
Mendes, R.V., Martins, A.R., de Nucci, G., Murad, F., and Soares, F.A. (2001). Expression of nitric oxide synthase isoforms and nitrotyrosine immunoreactivity by B-cell non-Hodgkin’s lymphomas and multiple myeloma. Histopathology 39: 172–178, https://doi.org/10.1046/j.1365-2559.2001.01189.x.Search in Google Scholar
Munoz-Sanchez, J. and Chanez-Cardenas, M.E. (2019). The use of cobalt chloride as a chemical hypoxia model. J. Appl. Toxicol. 39: 556–570, https://doi.org/10.1002/jat.3749.Search in Google Scholar
Nakayama, J., Rice, J.C., Strahl, B.D., Allis, C.D., and Grewal, S.I. (2001). Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292: 110–113, https://doi.org/10.1126/science.1060118.Search in Google Scholar
Prueitt, R.L., Boersma, B.J., Howe, T.M., Goodman, J.E., Thomas, D.D., Ying, L., Pfiester, C.M., Yfantis, H.G., Cottrell, J.R., Lee, D.H., Remaley, A.T., Hofseth, L.J., Wink, D.A., and Ambs, S. (2007). Inflammation and IGF-I activate the Akt pathway in breast cancer. Int. J. Cancer 120: 796–805, https://doi.org/10.1002/ijc.22336.Search in Google Scholar
Rao, C.V., Indranie, C., Simi, B., Manning, P.T., Connor, J.R., and Reddy, B.S. (2002). Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 62: 165–170.Search in Google Scholar
Ridnour, L.A., Barasch, K.M., Windhausen, A.N., Dorsey, T.H., Lizardo, M.M., Yfantis, H.G., Lee, D.H., Switzer, C.H., Cheng, R.Y., Heinecke, J.L., et al.. (2012). Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PloS One 7: e44081, https://doi.org/10.1371/journal.pone.0044081.Search in Google Scholar
Sabari, B.R., Zhang, D., Allis, C.D., and Zhao, Y. (2017). Metabolic regulation of gene expression through histone acylations. Nat. Rev. Mol. Cell Biol. 18: 90–101, https://doi.org/10.1038/nrm.2016.140.Search in Google Scholar
Sahni, S., Hickok, J.R., and Thomas, D.D. (2018). Nitric oxide reduces oxidative stress in cancer cells by forming dinitrosyliron complexes. Nitric Oxide 76: 37–44, https://doi.org/10.1016/j.niox.2018.03.003.Search in Google Scholar
Shiva, S., Brookes, P.S., Patel, R.P., Anderson, P.G., and Darley-Usmar, V.M. (2001). Nitric oxide partitioning into mitochondrial membranes and the control of respiration at cytochrome c oxidase. Proc. Natl. Acad. Sci. U.S.A. 98: 7212–7217, https://doi.org/10.1073/pnas.131128898.Search in Google Scholar
Socco, S., Bovee, R.C., Palczewski, M.B., Hickok, J.R., and Thomas, D.D. (2017). Epigenetics: the third pillar of nitric oxide signaling. Pharmacol. Res. 121: 52–58, https://doi.org/10.1016/j.phrs.2017.04.011.Search in Google Scholar
Switzer, C.H., Cheng, R.Y., Ridnour, L.A., Glynn, S.A., Ambs, S., and Wink, D.A. (2012a). Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 14: R125, https://doi.org/10.1186/bcr3319.Search in Google Scholar
Switzer, C.H., Glynn, S.A., Ridnour, L.A., Cheng, R.Y., Vitek, M.P., Ambs, S., and Wink, D.A. (2011). Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol. Sci. 32: 644–651, https://doi.org/10.1016/j.tips.2011.07.001.Search in Google Scholar
Switzer, C.H., Ridnour, L.A., Cheng, R., Heinecke, J., Burke, A., Glynn, S., Ambs, S., and Wink, D.A. (2012b). S-Nitrosation mediates multiple pathways that lead to tumor progression in estrogen receptor-negative breast cancer. For. Immunopathol. Dis. Therap. 3: 117–124, https://doi.org/10.1615/forumimmundisther.2012006108.Search in Google Scholar
Thomas, D.D. (2015). Breathing new life into nitric oxide signaling: a brief overview of the interplay between oxygen and nitric oxide. Redox Biol. 5: 225–233, https://doi.org/10.1016/j.redox.2015.05.002.Search in Google Scholar
Thomas, D.D., Heinecke, J.L., Ridnour, L.A., Cheng, R.Y., Kesarwala, A.H., Switzer, C.H., McVicar, D.W., Roberts, D.D., Glynn, S., Fukuto, J.M., et al.. (2015). Signaling and stress: the redox landscape in NOS2 biology. Free Radic. Biol. Med. 87: 204–225, https://doi.org/10.1016/j.freeradbiomed.2015.06.002.Search in Google Scholar
Vasudevan, D., Bovee, R.C., and Thomas, D.D. (2016). Nitric oxide, the new architect of epigenetic landscapes. Nitric Oxide 59: 54–62, https://doi.org/10.1016/j.niox.2016.08.002.Search in Google Scholar
Vasudevan, D., Hickok, J.R., Bovee, R.C., Pham, V., Mantell, L.L., Bahroos, N., Kanabar, P., Cao, X.J., Maienschein-Cline, M., Garcia, B.A., and Thomas, D.D. (2015). Nitric oxide regulates gene expression in cancers by controlling histone posttranslational modifications. Cancer Res. 75: 5299–5308, https://doi.org/10.1158/0008-5472.can-15-1582.Search in Google Scholar
Vasudevan, D. and Thomas, D.D. (2014). Insights into the diverse effects of nitric oxide on tumor biology. Vitam. Horm. 96: 265–298, https://doi.org/10.1016/b978-0-12-800254-4.00011-8.Search in Google Scholar
Zhang, L., Zhang, J., Jiang, Q., Zhang, L., and Song, W. (2018). Zinc binding groups for histone deacetylase inhibitors. J. Enzyme Inhib. Med. Chem. 33: 714–721, https://doi.org/10.1080/14756366.2017.1417274.Search in Google Scholar
Zhang, Y. and Reinberg, D. (2001). Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 15: 2343–2360, https://doi.org/10.1101/gad.927301.Search in Google Scholar
Zhao, L., Okhovat, J.P., Hong, E.K., Kim, Y.H., and Wood, G.S. (2019). Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma. Neoplasia 21: 82–92, https://doi.org/10.1016/j.neo.2018.11.006.Search in Google Scholar
© 2021 Walter de Gruyter GmbH, Berlin/Boston
